Jean-François Labbé, President and CEO of SpePharm commented: "Following marketing approval and this initial launch in the UK, further launches of Loramyc will follow as other national marketing authorisations are granted, and SpePharm continues to aggressively put in place its sales and marketing infrastructure throughout Europe".
Mike Stowe, SpePharm UK Ltd Managing Director added: "We all feel very positive about the UK launch of Loramyc as the initial feedback from specialists indicates a real need for this product due to the lack of optimal efficacy and compliance issues with currently available products. Although guidelines recommend the first line use of a topical buccal treatment for OPC, in many cases specialists are being forced to move immediately to systemic drugs with the attendant risks of generating both resistance and potentially severe drug-drug interactions. We believe that Loramyc is the only topical, once-daily, effective treatment for OPC in this important group of immuno-compromised patients."
SpePharm Holding, B.V. is a Dutch company with its registered office in Amsterdam, and its European operations based in Paris, France. SpePharm is an emerging pan-European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines essentially for the hospital markets. Particular areas of therapeutic interest are oncology, critical and supportive care. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. SpePharm was founded in September 2006 by Jean-François Labbé together with leading life science investment firms TVM Capital and Signet Healthcare Partners (part of the Sanders Morris Harris Group). Jean-François Labbé is a former top executive of Hoechst Marion Roussel and Parke Davis with over 30 years of experience in international pharmaceutical management. SpePharm, through its founding management team, has a proven track record of successful development, registration, and commercialization of quality therapeutic products in supportive & critical care, oncology and in orphan diseases. To date SpePharm has an established commercial presence in the UK, Germany, Italy, Benelux and the Nordic area.
Loramyc, muco-adhesive buccal tablets containing miconazole (50 mg), provides an innovative delivery system for the product which was developed by BioAlliance Pharma S.A. for the treatment of oropharyngeal candidiasis (OPC) in immuno-compromised patients. In October 2006, BioAlliance obtained a marketing authorization for Loramyc in France. In December 2007, the product obtained regulatory approval across Europe under the European Mutual Recognition Procedure (MRP) with France as the Reference Member State. To date national approvals have been granted in the UK, Denmark, Germany, Belgium, The Netherlands, Finland, Luxembourg and Sweden under the trade name Loramyc, as well as in Spain under the trade name Sitamic. National approval processes are ongoing in the other European countries involved in the MRP.
This email, its content and any files transmitted with it are confidential and are intended only for the addressee. If you are not the addressee, you may not print, copy, use or rely on the contents, attachments or information in any way except with the express written permission of the sender. If this email has been sent to you in error please destroy it and contact the sender. This email has been prepared using information believed by the author to be reliable and accurate, but College Hill makes no warranty as to its accuracy or completeness. In particular, College Hill does not accept changes made to this email after it was sent.
This is cache, read story here